(CRBG) Corebridge Financial - Ratings and Ratios

Corebridge Financial, Inc. (NYSE:CRBG) is a leading provider of retirement solutions and insurance products in the United States, operating through four distinct segments: Individual Retirement, Group Retirement, Life Insurance, and Institutional Markets. The Individual Retirement segment specializes in a range of annuity products, including fixed, fixed index, registered index-linked, and variable annuities, designed to meet diverse retirement needs. The Group Retirement segment offers a comprehensive suite of in-plan and out-of-plan solutions, including an open architecture recordkeeping platform, flexible group annuities, and investment advisory services. This segment also provides brokerage services for a variety of financial products, including mutual funds, securities, and 529 plans. The Life Insurance segment delivers a portfolio of life insurance products, such as term, whole, index universal, and guaranteed universal life insurance, catering to individual protection and estate planning needs. The Institutional Markets segment focuses on serving institutional clients with defined contribution plans, stable value wraps, structured settlement annuities, pension risk transfer solutions, and private placement products. Formerly known as SAFG Retirement Services, Inc., Corebridge Financial, Inc. was incorporated in 1998 and is headquartered in Houston, Texas. The company is well-established in the financial services industry, with a strong focus on retirement and insurance solutions.

Looking ahead, Corebridge Financial, Inc. is expected to maintain its stable operational performance. Based on the provided and , here is a 3-month forecast: The stock is currently trading at $28.25, slightly below its 20-day SMA of $28.88 but above its 200-day SMA of $29.89, indicating a neutral short-term trend with potential upside. The 50-day SMA at $31.00 suggests a resistance level that could cap near-term gains. With an ATR of 1.54, volatility is moderate, allowing for a projected price range of $26.71 to $29.79 over the next three months. Fundamentally, the companys P/E of 6.91 and forward P/E of 5.05 indicate undervaluation relative to earnings expectations, supported by a robust RoE of 19.46%. The P/B ratio of 1.24 and P/S of 0.76 further highlight its attractive valuation metrics, positioning the stock for potential upside as market conditions stabilize.